Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23055053 | 0.85 | HDAC1 (0.48) | HDAC1HDAC3HDAC2HDAC11KCNH2 | |
| SCHEMBL23054889 | 0.82 | HDAC1 (0.64) | HDAC1HDAC3HDAC2HDAC11KCNH2 | |
| SCHEMBL18415621 | 0.78 | HDAC1 (0.53) | HDAC1HDAC3HDAC2HDAC11KCNH2 | |
| SCHEMBL23054860 | 0.78 | HDAC1 (0.61) | HDAC1HDAC3HDAC2HDAC11KCNH2 | |
| SCHEMBL23055050 | 0.78 | HTR2A (0.50) | HDAC1HDAC3HDAC2HDAC11KCNH2 | |
| SCHEMBL23054891 | 0.77 | HDAC1 (0.51) | HDAC1HDAC3HDAC2HDAC11KCNH2 | |
| SCHEMBL20232415 | 0.77 | HDAC1 (0.69) | HDAC1HDAC3HDAC2HDAC11KCNH2 | |
| SCHEMBL23054983 | 0.75 | ATM (0.59) | HDAC1HDAC3HDAC2HDAC11PABPC1 | |
| SCHEMBL24758494 | 0.72 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC11KCNH2 | |
| SCHEMBL23054930 | 0.72 | HDAC1 (0.62) | HDAC1HDAC3HDAC2HDAC11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC3 1/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.